Moleculin Biotech Reports Significant Progress
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 18 2026
0mins
Should l Buy MBRX?
Source: stocktwits
- Clinical Trial Progress: Moleculin Biotech is on track to treat the 45th subject in Q1 2026, having treated 35 subjects so far with another 11 in screening, setting the stage for subsequent data unblinding.
- Preliminary Efficacy Results: Among the first 30 patients treated with Annamycin, a preliminary composite complete remission (CRc) rate of 40% was reported, indicating promising early efficacy and safety for the drug in acute myeloid leukemia (AML) patients.
- Positive Market Reaction: Following the announcement, Moleculin's shares rose by 14%, reflecting investor optimism regarding the clinical trial results, despite the stock having lost approximately 89% over the past year.
- Social Media Sentiment: On Stocktwits, retail sentiment around MRX stock remained in the 'bullish' territory, with message volume increasing from 'normal' to 'high', as users expressed optimism about the upcoming data unblinding, suggesting explosive potential if results are favorable.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MBRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MBRX
Wall Street analysts forecast MBRX stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.960
Low
20.00
Averages
24.33
High
31.00
Current: 1.960
Low
20.00
Averages
24.33
High
31.00
About MBRX
Moleculin Biotech, Inc. is a Phase III clinical-stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing tumors and viruses. The Company is conducting a pivotal Phase III trial evaluating Annamycin, a non-cardiotoxic anthracycline, in combination with Cytarabine for the treatment of subjects with relapsed/refractory acute myeloid leukemia (AML). It has three core technologies and six drug candidates, three of which have shown human activity in clinical trials. Its core technologies consist of Annamycin, WP1066 Portfolio, and WP1122 Portfolio. Annamycin is designed to avoid multidrug resistance mechanisms and cardiotoxicity. Its WP1066, is an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other transcription factors, and its portfolio includes WP1193, and WP1220. Its WP1122 contains compounds including WP1096, and WP1097, which is designed to exploit the potential uses of inhibitors of glycolysis such as 2-deoxy-D-glucose (2-DG).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
U.S. Stocks Close Lower, Dow Jones Falls Over 300 Points
- Market Performance: U.S. stocks closed lower on Thursday, with the Dow Jones index dropping over 300 points, a decline of 0.64% to 49,346.38, indicating investor concerns about the economic outlook.
- Walmart Earnings: Walmart reported upbeat fourth-quarter results with adjusted earnings per share of 74 cents, exceeding the expected 73 cents, but its fiscal 2027 outlook fell short, projecting earnings between $2.75 and $2.85, below the consensus estimate of $2.96.
- Sales Growth: Walmart's sales reached $190.70 billion, a 5.6% year-over-year increase, surpassing the analyst consensus of $190.43 billion, demonstrating the company's strong performance in the retail market.
- Energy Stocks Rise: Despite the overall market decline, energy stocks gained 1.1%, reflecting investor confidence in the sector, likely driven by oil prices rising 2.1% to $66.53.
See More
U.S. Stocks Open Lower with Dow Down Over 250 Points
- Market Performance: U.S. stocks opened lower this morning, with the Dow Jones index dropping over 250 points, a decline of 0.54% to 49,394.62, indicating weakened market sentiment that could impact investor confidence.
- Jobless Claims Data: Initial jobless claims in the U.S. fell by 23,000 to 206,000, below market expectations of 225,000, suggesting a resilient labor market that may positively influence economic recovery.
- Energy Stocks Rise: Energy shares gained 1.5% on Thursday, reflecting optimistic expectations for energy demand, which could present profit growth opportunities for related companies.
- Commodity Market Dynamics: Oil prices increased by 2.1% to $66.55, while gold rose 0.1% to $5,012.00, indicating heightened demand for safe-haven assets, which may influence future investment strategies.
See More
Moleculin Biotech Exercises Warrants for $8.3M
- Financing Scale: Moleculin Biotech has entered agreements for the immediate exercise of warrants covering 2.12 million shares at $3.90 each, expected to generate approximately $8.3 million in gross proceeds before advisory fees, thereby enhancing the company's liquidity.
- New Warrants Issuance: The company will issue new unregistered five-year warrants to purchase up to 6.37 million shares, with an exercise price set at the lower of $3.90 or the lowest VWAP during the next five trading days, increasing financing flexibility.
- Use of Proceeds: The transaction is expected to close around February 20, 2026, with net proceeds allocated for working capital and general corporate purposes, indicating the company's proactive planning for future operations.
- Market Reaction: The exercise of warrants and the new issuance plan may boost market confidence in Moleculin Biotech's financial health, potentially leading to a positive impact on its stock price.
See More
Moleculin Biotech Reports Significant Progress
- Clinical Trial Progress: Moleculin Biotech is on track to treat the 45th subject in Q1 2026, having treated 35 subjects so far with another 11 in screening, setting the stage for subsequent data unblinding.
- Preliminary Efficacy Results: Among the first 30 patients treated with Annamycin, a preliminary composite complete remission (CRc) rate of 40% was reported, indicating promising early efficacy and safety for the drug in acute myeloid leukemia (AML) patients.
- Positive Market Reaction: Following the announcement, Moleculin's shares rose by 14%, reflecting investor optimism regarding the clinical trial results, despite the stock having lost approximately 89% over the past year.
- Social Media Sentiment: On Stocktwits, retail sentiment around MRX stock remained in the 'bullish' territory, with message volume increasing from 'normal' to 'high', as users expressed optimism about the upcoming data unblinding, suggesting explosive potential if results are favorable.
See More
Moleculin Biotech Reports Progress in Annamycin Clinical Trial
- Promising Efficacy: Moleculin Biotech reports a preliminary complete remission rate (CRc) of 40% in the MIRACLE trial, with a complete remission (CR) rate of 30%, indicating Annamycin's potential to significantly improve outcomes for relapsed/refractory acute myeloid leukemia (R/R AML) patients.
- Recruitment Progress: To date, 35 subjects have been treated, with plans to complete treatment for 45 subjects by Q1 2026, followed by data unblinding, which is expected to provide critical insights for future partnerships and value inflection points for the company.
- Safety Profile: Annamycin has demonstrated no cardiotoxicity in prior trials involving 90 patients, and combined with current efficacy data, it is anticipated to offer a new treatment avenue for AML patients, addressing the urgent market need for non-cardiotoxic therapies.
- Strong Market Demand: The MIRACLE trial is being conducted across six countries, highlighting the significant unmet medical need among R/R AML patients, which is expected to drive market acceptance and future commercial opportunities for Annamycin.
See More
Moleculin Biotech Inc. Announces 40% Preliminary CRC Rate in Miracle Trial
Preliminary Results: Moleculin Biotech reports a 40% preliminary complete response rate in its clinical trial for the drug Miraclin.
Clinical Trial Focus: The trial is focused on evaluating the efficacy of Miraclin in treating specific medical conditions.
See More
U.S. Stocks Close Lower, Dow Jones Falls Over 300 Points
- Market Performance: U.S. stocks closed lower on Thursday, with the Dow Jones index dropping over 300 points, a decline of 0.64% to 49,346.38, indicating investor concerns about the economic outlook.
- Walmart Earnings: Walmart reported upbeat fourth-quarter results with adjusted earnings per share of 74 cents, exceeding the expected 73 cents, but its fiscal 2027 outlook fell short, projecting earnings between $2.75 and $2.85, below the consensus estimate of $2.96.
- Sales Growth: Walmart's sales reached $190.70 billion, a 5.6% year-over-year increase, surpassing the analyst consensus of $190.43 billion, demonstrating the company's strong performance in the retail market.
- Energy Stocks Rise: Despite the overall market decline, energy stocks gained 1.1%, reflecting investor confidence in the sector, likely driven by oil prices rising 2.1% to $66.53.
See More
U.S. Stocks Open Lower with Dow Down Over 250 Points
- Market Performance: U.S. stocks opened lower this morning, with the Dow Jones index dropping over 250 points, a decline of 0.54% to 49,394.62, indicating weakened market sentiment that could impact investor confidence.
- Jobless Claims Data: Initial jobless claims in the U.S. fell by 23,000 to 206,000, below market expectations of 225,000, suggesting a resilient labor market that may positively influence economic recovery.
- Energy Stocks Rise: Energy shares gained 1.5% on Thursday, reflecting optimistic expectations for energy demand, which could present profit growth opportunities for related companies.
- Commodity Market Dynamics: Oil prices increased by 2.1% to $66.55, while gold rose 0.1% to $5,012.00, indicating heightened demand for safe-haven assets, which may influence future investment strategies.
See More
Moleculin Biotech Exercises Warrants for $8.3M
- Financing Scale: Moleculin Biotech has entered agreements for the immediate exercise of warrants covering 2.12 million shares at $3.90 each, expected to generate approximately $8.3 million in gross proceeds before advisory fees, thereby enhancing the company's liquidity.
- New Warrants Issuance: The company will issue new unregistered five-year warrants to purchase up to 6.37 million shares, with an exercise price set at the lower of $3.90 or the lowest VWAP during the next five trading days, increasing financing flexibility.
- Use of Proceeds: The transaction is expected to close around February 20, 2026, with net proceeds allocated for working capital and general corporate purposes, indicating the company's proactive planning for future operations.
- Market Reaction: The exercise of warrants and the new issuance plan may boost market confidence in Moleculin Biotech's financial health, potentially leading to a positive impact on its stock price.
See More
Moleculin Biotech Reports Significant Progress
- Clinical Trial Progress: Moleculin Biotech is on track to treat the 45th subject in Q1 2026, having treated 35 subjects so far with another 11 in screening, setting the stage for subsequent data unblinding.
- Preliminary Efficacy Results: Among the first 30 patients treated with Annamycin, a preliminary composite complete remission (CRc) rate of 40% was reported, indicating promising early efficacy and safety for the drug in acute myeloid leukemia (AML) patients.
- Positive Market Reaction: Following the announcement, Moleculin's shares rose by 14%, reflecting investor optimism regarding the clinical trial results, despite the stock having lost approximately 89% over the past year.
- Social Media Sentiment: On Stocktwits, retail sentiment around MRX stock remained in the 'bullish' territory, with message volume increasing from 'normal' to 'high', as users expressed optimism about the upcoming data unblinding, suggesting explosive potential if results are favorable.
See More
Moleculin Biotech Reports Progress in Annamycin Clinical Trial
- Promising Efficacy: Moleculin Biotech reports a preliminary complete remission rate (CRc) of 40% in the MIRACLE trial, with a complete remission (CR) rate of 30%, indicating Annamycin's potential to significantly improve outcomes for relapsed/refractory acute myeloid leukemia (R/R AML) patients.
- Recruitment Progress: To date, 35 subjects have been treated, with plans to complete treatment for 45 subjects by Q1 2026, followed by data unblinding, which is expected to provide critical insights for future partnerships and value inflection points for the company.
- Safety Profile: Annamycin has demonstrated no cardiotoxicity in prior trials involving 90 patients, and combined with current efficacy data, it is anticipated to offer a new treatment avenue for AML patients, addressing the urgent market need for non-cardiotoxic therapies.
- Strong Market Demand: The MIRACLE trial is being conducted across six countries, highlighting the significant unmet medical need among R/R AML patients, which is expected to drive market acceptance and future commercial opportunities for Annamycin.
See More
Moleculin Biotech Inc. Announces 40% Preliminary CRC Rate in Miracle Trial
Preliminary Results: Moleculin Biotech reports a 40% preliminary complete response rate in its clinical trial for the drug Miraclin.
Clinical Trial Focus: The trial is focused on evaluating the efficacy of Miraclin in treating specific medical conditions.
See More
